Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C.

Gynecol Oncol. 2019 Oct 15. pii: S0090-8258(19)31548-3. doi: 10.1016/j.ygyno.2019.09.024. [Epub ahead of print]

PMID:
31623857
2.

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707. [Epub ahead of print]

PMID:
31562800
3.

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.

Dockery LE, Rubenstein AR, Ding K, Mashburn SG, Burkett WC, Davis AM, Doo DW, Arend RC, Moore KN, Gunderson CC.

Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31394-0. doi: 10.1016/j.ygyno.2019.07.008. [Epub ahead of print]

PMID:
31522837
4.

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.

Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN.

J Clin Oncol. 2019 Sep 5:JCO1900739. doi: 10.1200/JCO.19.00739. [Epub ahead of print]

PMID:
31487218
5.

Olaparib in the treatment of ovarian cancer.

Washington CR, Richardson DL, Moore KN.

Future Oncol. 2019 Sep 3. doi: 10.2217/fon-2019-0271. [Epub ahead of print]

PMID:
31478762
6.

In Trauma-Exposed Individuals, Self-Reported Hyperarousal and Sleep Architecture Predict Resting-State Functional Connectivity in Frontocortical and Paralimbic Regions.

Seo J, Oliver KI, Daffre C, Moore KN, Lasko NB, Pace-Schott EF.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Jul 9. pii: S2451-9022(19)30179-X. doi: 10.1016/j.bpsc.2019.06.013. [Epub ahead of print]

PMID:
31455572
7.

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.

Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA.

Gynecol Oncol. 2019 Oct;155(1):69-74. doi: 10.1016/j.ygyno.2019.07.020. Epub 2019 Aug 10.

PMID:
31409486
8.

Tissue response to applied loading using different designs of penile compression clamps.

Lemmens JM, Broadbridge J, Macaulay M, Rees RW, Archer M, Drake MJ, Moore KN, Bader DL, Fader M.

Med Devices (Auckl). 2019 Jun 27;12:235-243. doi: 10.2147/MDER.S188888. eCollection 2019.

9.

From the battlefield to main street: Tourniquet acceptance, use, and translation from the military to civilian settings.

Goodwin T, Moore KN, Pasley JD, Troncoso R Jr, Levy MJ, Goolsby C.

J Trauma Acute Care Surg. 2019 Jul;87(1S Suppl 1):S35-S39. doi: 10.1097/TA.0000000000002198.

PMID:
31246904
10.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

11.

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE.

Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4.

PMID:
31174889
12.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
13.

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.

Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.

PMID:
30887020
14.

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

Birrer MJ, Moore KN, Betella I, Bates RC.

J Natl Cancer Inst. 2019 Mar 11. pii: djz035. doi: 10.1093/jnci/djz035. [Epub ahead of print]

PMID:
30859213
15.

Simple Hysterectomy for Cervical Cancer: Risk Factors for Failed Screening and Deviation From Screening Guidelines.

Castellano T, Ding K, Moore KN, Landrum LM.

J Low Genit Tract Dis. 2019 Apr;23(2):124-128. doi: 10.1097/LGT.0000000000000463.

PMID:
30817687
16.

Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

Naumann RW, Coleman RL, Brown J, Moore KN.

Gynecol Oncol. 2019 May;153(2):436-444. doi: 10.1016/j.ygyno.2019.02.008. Epub 2019 Feb 12. Review.

PMID:
30765149
17.

From the Battlefield to Main Street: Tourniquet Acceptance, Use, and Translation from the Military to Civilian Settings.

Goodwin T, Moore KN, Pasley JD, Troncoso R Jr, Levy MJ, Goolsby C.

J Trauma Acute Care Surg. 2019 Jan 18. doi: 10.1097/TA.0000000000002198. [Epub ahead of print]

PMID:
30664036
18.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA.

Gynecol Oncol. 2019 Mar;152(3):560-567. doi: 10.1016/j.ygyno.2018.12.009. Epub 2019 Jan 9.

19.

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Birrer MJ, Betella I, Martin LP, Moore KN.

Oncologist. 2019 Apr;24(4):425-429. doi: 10.1634/theoncologist.2018-0459. Epub 2019 Jan 11. No abstract available.

PMID:
30635448
21.

Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.

Gunderson CC, Erickson BK, Wilkinson-Ryan I, Vesely SK, Leath CA 3rd, Gehrig PA, Moore KN.

Am J Clin Oncol. 2019 Feb;42(2):138-142. doi: 10.1097/COC.0000000000000498.

PMID:
30557164
22.

Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.

Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C.

Oncologist. 2019 Apr;24(4):455-e121. doi: 10.1634/theoncologist.2018-0740. Epub 2018 Nov 26.

23.

Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.

Washington C, Gunderson CC, Moore KN.

Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.

PMID:
30451713
24.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.

Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.

Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

PMID:
30413525
25.

Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer.

Richardson DL, Seward SM, Moore KN.

Hematol Oncol Clin North Am. 2018 Dec;32(6):1057-1071. doi: 10.1016/j.hoc.2018.07.014. Epub 2018 Oct 1. Review.

PMID:
30390760
26.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC.

Invest New Drugs. 2019 Jun;37(3):461-472. doi: 10.1007/s10637-018-0665-y. Epub 2018 Sep 19.

PMID:
30229512
27.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM.

Gynecol Oncol. 2018 Nov;151(2):202-207. doi: 10.1016/j.ygyno.2018.08.006. Epub 2018 Aug 31.

PMID:
30174176
28.

Reuse of intermittent catheters: a qualitative study of IC users' perspectives.

Avery M, Prieto J, Okamoto I, Cullen S, Clancy B, Moore KN, Macaulay M, Fader M.

BMJ Open. 2018 Aug 17;8(8):e021554. doi: 10.1136/bmjopen-2018-021554.

29.

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.

Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.

Gynecol Oncol. 2018 Oct;151(1):46-52. doi: 10.1016/j.ygyno.2018.07.017. Epub 2018 Aug 6.

30.

First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.

Moore KN, Bendell JC, LoRusso PM, Olszanski AJ, Zwick-Wallasch E, Jansen M, Vandell AG, Senaldi G.

Invest New Drugs. 2019 Feb;37(1):147-158. doi: 10.1007/s10637-018-0646-1. Epub 2018 Jul 28.

PMID:
30056611
31.

Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.

Buechel M, Dey A, Dwivedi SKD, Crim A, Ding K, Zhang R, Mukherjee P, Moore KN, Cao L, Branstrom A, Weetall M, Baird J, Bhattacharya R.

Mol Cancer Ther. 2018 Oct;17(10):2136-2143. doi: 10.1158/1535-7163.MCT-17-1192. Epub 2018 Jul 19.

32.

Niraparib for the treatment of ovarian cancer.

Essel KG, Moore KN.

Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2. Review.

PMID:
29911447
33.

Delayed fear extinction in individuals with insomnia disorder.

Seo J, Moore KN, Gazecki S, Bottary RM, Milad MR, Song H, Pace-Schott EF.

Sleep. 2018 Aug 1;41(8). doi: 10.1093/sleep/zsy095.

34.

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA.

Clin Cancer Res. 2018 Nov 15;24(22):5525-5533. doi: 10.1158/1078-0432.CCR-18-0494. Epub 2018 May 29.

PMID:
29844129
35.

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC.

Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076.

PMID:
29788155
36.

Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM.

Gynecol Oncol. 2018 Jun;149(3):605-611. doi: 10.1016/j.ygyno.2018.04.008. Epub 2018 Apr 24. Review.

PMID:
29699802
37.

Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.

McClurg D, Bugge C, Elders A, Irshad T, Hagen S, Moore KN, Buckley B, Fader M.

Mult Scler. 2019 Apr;25(5):727-739. doi: 10.1177/1352458518768722. Epub 2018 Apr 23.

PMID:
29683042
38.

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN.

Clin Cancer Res. 2018 Jul 15;24(14):3253-3262. doi: 10.1158/1078-0432.CCR-17-3421. Epub 2018 Apr 10.

39.

Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.

Dockery LE, Motwani A, Ding K, Doescher M, Dvorak JD, Moore KN, Holman LL.

Gynecol Oncol. 2018 Apr;149(1):89-92. doi: 10.1016/j.ygyno.2017.10.023.

PMID:
29605056
40.

Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.

Buechel M, McGinnis A, Vesely SK, Wade KS, Moore KN, Gunderson CC.

Gynecol Oncol. 2018 Apr;149(1):28-32. doi: 10.1016/j.ygyno.2017.11.021.

PMID:
29605046
41.

Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.

Moore KN, Birrer MJ.

Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28. Review.

42.

Development of a Quantitative LC-MS-MS Assay for Codeine, Morphine, 6-Acetylmorphine, Hydrocodone, Hydromorphone, Oxycodone and Oxymorphone in Neat Oral Fluid.

Grabenauer M, Moore KN, Bynum ND, White RM, Mitchell JM, Hayes ED, Flegel R.

J Anal Toxicol. 2018 Jul 1;42(6):392-399. doi: 10.1093/jat/bky021.

PMID:
29554298
43.

An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.

Castellano T, Moore KN, Holman LL.

Clin Ther. 2018 Mar;40(3):372-388. doi: 10.1016/j.clinthera.2018.01.005. Epub 2018 Mar 9. Review.

PMID:
29530456
44.

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR.

ESMO Open. 2018 Feb 1;3(2):e000291. doi: 10.1136/esmoopen-2017-000291. eCollection 2018.

45.

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ.

Future Oncol. 2018 Jul;14(17):1669-1678. doi: 10.2217/fon-2017-0646. Epub 2018 Feb 9.

46.

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF.

Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023.

PMID:
29401246
47.

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.

Moore KN, Mirza MR, Matulonis UA.

Gynecol Oncol. 2018 Apr;149(1):214-220. doi: 10.1016/j.ygyno.2018.01.011. Epub 2018 Feb 4. Review.

PMID:
29397193
48.

Management of the toxicities of common targeted therapeutics for gynecologic cancers.

Gunderson CC, Matulonis U, Moore KN.

Gynecol Oncol. 2018 Mar;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010. Epub 2018 Feb 1. Review.

PMID:
29395304
49.

Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.

Hagemann AR, McCourt CK, Varaday SS, Moore KN.

Gynecol Oncol. 2018 Mar;148(3):601-608. doi: 10.1016/j.ygyno.2017.12.020. Epub 2018 Jan 10. Review.

PMID:
29329881
50.

Detection and quantification of codeine-6-glucuronide, hydromorphone-3-glucuronide, oxymorphone-3-glucuronide, morphine 3-glucuronide and morphine-6-glucuronide in human hair from opioid users by LC-MS-MS.

Grabenauer M, Bynum ND, Moore KN, White RM, Mitchell JM, Hayes ED, Flegel R.

J Anal Toxicol. 2018 Mar 1;42(2):115-125. doi: 10.1093/jat/bkx086.

PMID:
29186453

Supplemental Content

Loading ...
Support Center